Product Pipeline

We are developing novel checkpoint inhibitors and immuno-oncology therapies that we believe may overcome some of the limitations of current immuno-oncology therapies. Three of these programs are aimed at disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment or by blocking its production by tumors. Other programs are aimed at regulating T-cell activation or myeloid cell suppression.

Adenosine A2A Receptor Antagonist CPI-444
Adenosine Production Inhibitor Anti-CD73
Adenosine A2B Receptor Antagonist
ITK Inhibitor
Myeloid Cell Suppression